Isoaspartate-glycine-arginine: A new tumor vasculature-targeting motif

Cancer Research

Volumn 68, Issue 17, 2008, Pages 7073-7082

  Curnis, Flavio ^a   Sacchi, Angelina ^a   Gasparri, Anna ^a   Longhi, Renato ^b   Bachi, Angela ^a   Doglioni, Claudio ^a   Bordignon, Claudio ^c   Traversari, Catia ^c   Rizzardi, Gian Paolo ^c   Corti, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c MOLMED S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ISOASPARTYLGYLCYLARGININE; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; MONOCLONAL ANTIBODY PB 16; MONOCLONAL ANTIBODY WM 15; QUANTUM DOT; TRIPEPTIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; ENDOTHELIUM CELL; FIBROSARCOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN TARGETING; TUMOR VASCULARIZATION; WEIGHT REDUCTION; AMINO ACID SEQUENCE; ANIMAL; BLOOD VESSEL; C57BL MOUSE; DRUG EFFECT; MOLECULAR GENETICS; NEOPLASM; VASCULARIZATION;

AMINO ACID SEQUENCE; ANIMALS; BLOOD VESSELS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS; OLIGOPEPTIDES;

EID: 52049107824     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1272     Document Type: Article

References (41)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
2. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4.
3. Burrows FJ, Thorpe PE. Vascular targeting-a new approach to the therapy of solid tumors. Pharmacol Ther 1994;64:155-74.
4. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
5. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185-90.
6. Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A. Targeted delivery of IFNγ to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res 2005;65:2906-13.
7. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110:475-82.
8. Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor α and chemotherapeutic drugs. Ann N Y Acad Sci 2004;1028:104-12.
9. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A. Crucial role for interferon γ in the synergism between tumor vasculature-targeted tumor necrosis factor a (NGR-TNF) and doxorubicin. Cancer Res 2004;64:7150-5.
10. Zarovni N, Monaco L, Corti A. Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor α coupled to NGR and RGD tumor-homing peptides. Hum Gene Ther 2004;15:373-82.
11. Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-α. Clin Cancer Res 2006;12:175-82.
12. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7.
13. Curnis F, Arrigoni G, Sacchi A, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002;62:867-74.
14. Buehler A, van Zandvoort MA, Stelt BJ, et al. cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscler Thromb Vasc Biol 2006;26:2681-7.
15. von Wallbrunn A, WaldeckJ , Holtke C, et al. In vivo optical imaging of CD13/APN-expression in tumor xenografts. J Biomed Opt 2008;13:011007.
16. Curnis F, Longhi R, Crippa L, et al. Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem 2006;281:36466-76.
17. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin α v β 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22.
18. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins α v β 3 and α v β 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A 1996;93:9764-9.
19. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985;162:1745-59.
20. Di Matteo P, Curnis F, Longhi R, et al. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol Immunol 2006;43:1509-18.
21. Corti A, Poiesi C, Merli S, Cassani G. Tumor necrosis factor (TNF) α quantification by ELISA and bioassay: effects of TNF α-soluble TNF receptor (p55) complex dissociation during assay incubations. J Immunol Methods 1994;177:191-8.
22. Gasparri A, Moro M, Curnis F, et al. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor α in mouse models. Cancer Res 1999;59:2917-23.
23. Colombo G, Curnis F, De Mori GM, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 2002;277:47891-7.
24. Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A. Coupling tumor necrosis factor-α with αV integrin ligands improves its antineoplastic activity. Cancer Res 2004;64:565-71.
25. Corti A, Fassina G, Marcucci F, Barbanti E, Cassani G. Oligomeric tumour necrosis factor α slowly converts into inactive forms at bioactive levels. Biochem J 1992;284:905-10.
26. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 1995;13:265-70.
27. Pastorino F, Brignole C, Di Paolo D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006;66:10073-82.
28. Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003;63:7400-9.
29. Garde SV, Forte AJ, Ge M, et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 2007;18:1189-200.
30. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5:1032-8.
31. Meng J, Ma N, Yan Z, Han W, Zhang Y. NGR enhanced the anti-angiogenic activity of tum-5. J Biochem (Tokyo) 2006;140:299-304.
32. Meng J, Yan Z, Wu J, et al. High-yield expression, purification and characterization of tumor-targeted IFN-α2a. Cytotherapy 2007;9:60-8.
33. Grifman M, Trepel M, Speece P, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001;3:964-75.
34. Mizuguchi H, Koizumi N, Hosono T, et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001;8:730-5.
35. Liu L, Anderson WF, Beart RW, Gordon EM, Hall FL. Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. J Virol 2000;74:5320-8.
36. Moffatt S, Cristiano RJ. Uptake characteristics of NGR-coupled stealth PEI/pDNA nanoparticles loaded with PLGA-PEG-PLGA tri-block copolymer for targeted delivery to human monocyte-derived dendritic cells. Int J Pharm 2006;321:143-54.
37. Holle L, Song W, Hicks L, et al. In vitro targeted killing of human endothelial cells by co-incubation of human serum and NGR peptide conjugated human albumin protein bearing α (1-3) galactose epitopes. Oncol Rep 2004;11:613-6.
38. Dirksen A, Langereis S, de Waal BF, et al. Design and synthesis of a bimodal target-specific contrast agent for angiogenesis. Org Lett 2004;6:4857-60.
39. Zhang Z, Harada H, Tanabe K, Hatta H, Hiraoka M, Nishimoto S. Aminopeptidase N/CD13 targeting fluorescent probes: synthesis and application to tumor cell imaging. Peptides 2005;26:2182-7.
40. Fuzery AK, Mihala N, Szabo P, Perczel A, Giavazzi R, Suli-Vargha H. Solution state conformation and degradation of cyclopeptides containing an NGR motif. J Pept Sci 2005;11:53-9.
41. Weber DJ, McFadden PN. Detection and characterization of a protein isoaspartyl methyltransferase which becomes trapped in the extracellular space during blood vessel injury. J Protein Chem 1997;16:257-67.